



AP32738 066876.0103
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Said I.A. SHALABY et al.
Serial No. : 09/955,877 Examiner : Patten, Patricia A.
Filed : September 19, 2001 Group Art Unit : 1654
For : HERBAL COMPOSITIONS AND TREATMENT METHODS

RECEIVED

FEB 02 2004

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

January 22, 2004

Date of Deposit

Carmella L. Stephens

Attorney Name

41,328

PTO Registration No.

Carmella L. Stephens

Signature

January 22, 2004

Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §1.56, Applicant respectfully requests that the documents relating to the above-identified application listed herein in reverse chronological alphabetical order be considered and made of record in the U.S. Patent and Trademark Office.

1. Harvard School of Public Health Jan 2004,

<http://www.researchmatters.harvard.edu/story.php?article_id=673>;

01/29/2004 JBALINAN 00000030 09955877

02 FC:1806

180.00 OP

NY02:472756.1

2. Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;
3. Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS , Wall Street Journal December 8, 2003
<<http://online.wsj.com/article/0,,SB107083909136415400-email,00.html>>;
4. Enfuvirtide (Fuzeon) for HIV Infection Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;
5. Abd El-Baset M et al, EP 0793964 published September 10, 1999;
6. El-Awady, et al., Chem. Clinical Acta, 283(1-2):1-14 (1999);
7. Kass HD et al., U.S. Patent No. 5,876,728 issued March 2, 1999;
8. Rogers SP, U.S. Patent No. 5,874,804 issued February 23, 1999;
9. McHutchison et al Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C, New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;
10. Yokozbawa, et al., J. Traditional Medicine,15(4):202-207 (1998);
11. Alter, M.J., Hepatology, 26(1):625-655 (1997);
12. Shawkat T, U.S. Patent No. 5,648,089 issued July 15, 1997;
13. Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);
14. D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);
15. Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);
16. D.C. Dale and D.D. Federman, eds. Medicine Sc. Amer., Inc., New York, 4(8):1-8 (1995);
17. Hipps, et al., Infect. Dis. 168:789-790 (1993);

18. Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);
19. Fields, Virology 2nd ed, New York, Raven Press, 1990 p691;
20. Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc.,
pp.150-51 (1983);
21. Medicinal Plants of North Africa, pp. 74-75 (1983);
22. Bergmeyer and Horder, Clin. Chem. Acta 105:147 f. (1980);
23. Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics,
p.169 (1980);
24. International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem.
Biochem.,18:521-534 (1980);
25. Bergmeyer H. U. Principles of Enzymatic Analysis. Verlag Chemic, (1978);
26. Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (1970); and
27. Linus Pauling, General Chemistry, New York, Raven Press 1970, p 744.


The referenced citations are listed in the accompanying PTO Form 1449. Copies of the documents will follow as soon as they are available. Identification of the documents listed in the attached PTO Form 1449 is not to be construed as an admission of Applicants or Attorneys for Applicants that such documents are available as "prior art" against the above-identified application.

Applicants enclose herewith the fees required pursuant to 37 C.F.R. §§ 1.17(p) and 1.97(c)(2). Applicants do not believe any additional fee is due with this submission. Nevertheless, the Commissioner is hereby authorized to deduct any fees required with this submission not otherwise enclosed herewith from Deposit Account No. 02-4377. Two copies of this paper are enclosed.

Respectfully submitted,

BAKER BOTTS, L.L.P.

January 22, 2004


Rochelle K. Seide
PTO Reg. No. 32,300

Carmella L. Stephens
PTO Reg. No. 41,328
Attorneys for Applicants

Guy F. Birkenmeier
PTO Reg. No. 52,622
Agent for Applicants

BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2500

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
	5 8 7 6 7 2 8	03/02/1999	Kass HD et al.			
	5 8 7 4 8 0 4	02/23/1999	Rogers SP			
	5 6 4 8 0 8 9	07/15/1997	Shawkat T			

FOREIGN PATENT DOCUMENT

Document No.	Date	Country	Class	SubClass	Translator Yes No
7 9 3 9 6 4	09/10/1999	Europe (EP)			

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	Harvard School of Public Health Jan 2004, < http://www.researchmatters.harvard.edu/story.php?article_id=673 >
	Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;
	Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS, Wall Street Journal December 8, 2003 < http://online.wsj.com/article/0,,SB107083909136415400-email,00.html >
	Enfuvirtide (Fuzeon) for HIV Infection Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;
	El-Awady, et al., Chem. Clinical Acta, 283(1-2):1-14 (1999)
	McHutchison et al Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C, New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;

NY02:472768.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654



Yokozbawa, et al., J. Traditional Medicine, 15(4):202-207 (1998)

Alter, M.J., Hepatology, 26(1):625-655 (1997)

Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);

D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);

Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);

D.C. Dale and D.D. Federman, eds. Medicine Sc. Amer., Inc., New York, 4(8):1-8 (1995);

Hipps, et al., Infect. Dis. 168:789-790 (1993);

Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);

Fields, Virology 2nd ed, New York, Raven Press, 1990 p691;

Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);

Medicinal Plants of North Africa, pp. 74-75 (1983);

Bergmeyer and Horder, Clin. Chem. Acta 105:147 f. (1980);

Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, p.169 (1980);

International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem. Biochem., 18:521-534 (1980);

NY02:472768.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654



Bergmeyer H. U. Principles of Enzymatic Analysis. Verlag Chemic, (1978);

Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (1970);

Linus Pauling, General Chemistry, New York, Raven Press 1970, p 744

NY02:472768.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.